| 4.05 0.02 (0.5%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.72 | 1-year : | 8.32 |
| Resists | First : | 5.75 | Second : | 7.13 |
| Pivot price | 5.39  |
|||
| Supports | First : | 3.52 | Second : | 2.93 |
| MAs | MA(5) : | 4.09 |
MA(20) : | 5.48 |
| MA(100) : | 4.94 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.7 |
D(3) : | 12.4 |
| RSI | RSI(14): 34.4 |
|||
| 52-week | High : | 7.13 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GALT ] has closed above bottom band by 14.9%. Bollinger Bands are 199.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.2 - 4.22 | 4.22 - 4.24 |
| Low: | 3.85 - 3.87 | 3.87 - 3.9 |
| Close: | 4.01 - 4.05 | 4.05 - 4.08 |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Wed, 24 Dec 2025
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha
Tue, 23 Dec 2025
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 - Investing.com
Sat, 20 Dec 2025
Galectin Therapeutics (GALT) Price Target Increased by 83.33% to 11.22 - Nasdaq
Fri, 19 Dec 2025
Why Did GALT Shares Plummet Over 30% Today? - Stocktwits
Fri, 19 Dec 2025
New funding keeps potential liver cirrhosis treatment on track to 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 29.7 (%) |
| Held by Institutions | 16 (%) |
| Shares Short | 6,820 (K) |
| Shares Short P.Month | 6,900 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -6.87 |
| PEG Ratio | 0 |
| Price to Book value | -2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|